C&D, Abbott settle patent dispute
This article was originally published in The Tan Sheet
Executive Summary
Abbott Labs will pay Church & Dwight $27 million to resolve allegations it infringed on three pregnancy diagnostic test kit patents, including two for "chemical analysis apparatus and method." The Sept. 17 settlement also says Abbott and device firm SurModics will not sue C&D for intellectual property infringement related to products that were the basis of a lawsuit. Abbott and SurModics must move to dismiss pending litigation against C&D, according to a Sept. 24 report C&D filed with the Securities and Exchange Commission. Abbott filed a 1complaint against C&D in June 2007, listing SurModics and Inverness Medical Switzerland as involuntary plaintiffs
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.